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Introduction:More detailed typing of non-small cell lung cancer on
small biopsy specimens is increasingly required, albeit sometimes
demanding with morphology alone. Little, however, is known about
the likelihood of immunohistochemistry (IHC)-assessed small biop-
sies to effectively parallel profiling and, hence, eventual diagnoses
of surgical specimens.
Methods: Sixty-three preoperative biopsies and the corresponding
surgical specimens from 30 consecutive squamous cell carcinomas,
22 adenocarcinomas, 2 adenosquamous carcinomas, eight sarcoma-
toid carcinomas, and one yolk sac tumor were jointly evaluated
semiquantitatively for cytokeratins 5/6 and 7, p63, thyroid transcrip-
tion factor-1, and vimentin immunoreactivity. Surgical specimens
were the gold standard for morphology and IHC.
Results: Hierarchic clustering analysis of both surgical specimens and
biopsies showed a nonrandom and overlapping distribution of the
relevant markers, which closely correlated with each other and the
diverse tumor categories, as confirmed by mosaic plot analysis. There
were no differences in area under the curve-receiver operating charac-
teristic curves for each marker between any two samples, with the
exception of p63 that paralleled more effectively squamous cell carci-
noma on biopsies than surgical specimens. Fifty-nine of 63 (94%)
lesions were correctly classified by IHC on biopsy compared with 53 of
63 (84%) by revised morphology, with the predictive positive value
being 97% for squamous cell carcinoma, 88% for adenocarcinoma, and
100% for sarcomatoid and adenosquamous carcinoma. Yolk sac tumor
and three of eight sarcomatoid carcinomas, however, failed any diag-
nostic recognition.
Conclusions: Diverse cell differentiation lineages of non-small cell
lung cancer may be consistently detected by IHC in small biopsies,
making the eventual typing of tumors effective in most cases.
Key Words: NSCLC, Morphology, Biopsy, Surgical specimens,
Immunohistochemistry, Diagnosis.
(J Thorac Oncol. 2011;6: 1039–1049)
Morphology has always been credited as the gold stan-dard in all World Health Organization lung cancer
classifications, based on the evaluation of surgically excised
specimens.1,2 Addressing small biopsies or cytology, how-
ever, may be demanding when exploiting morphology only3–5
for several independent reasons, such as poor differentiation,
artifacts, and the inherent heterogeneity of non-small cell
lung carcinomas (NSCLCs) (hence, the axiom, the more
tumor categories, the more difficulties in diagnosis).1,6–9
Worth stressing, however, is that small biopsies often are the
solely available material for patients with locally advanced or
metastatic disease at the time of diagnosis.10
For personalizing the most appropriate therapy, patholo-
gists have been requiring to provide more detailed diagnoses
beyond the compulsory distinction between small-cell lung car-
cinoma and NSCLC, in particular separating squamous cell
carcinoma from adenocarcinoma and large cell carcinoma.11 As
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morphology alone may be challenging, additional tools have
been steadily integrated into the pathologist’s diagnostic arma-
mentarium to increase the consistency of morphologic diagno-
ses,12 among which immunohistochemistry (IHC) has been
gaining large popularity as a simple, relatively inexpensive, and
reliable technique13–20 to unravel different cell lineages in lung
cancer, also when facing with either limited material17,18 or
poorly differentiated tumors.15,16 A simple antibody panel ap-
proach, including markers decorating squamous cells (high-
molecular-weight cytokeratin21 and p6322), gland-differentiated
elements (thyroid transcription factor-1 [TTF1]23,24 and cytoker-
atin 713,14,21), and tumor cells undergoing epithelial-mesenchy-
mal transition (vimentin),25,26 has been proposed to characterize
the main types of lung cancer.
There are, however, at least three issues to address when
dealing with the relevance of IHC to lung cancer characteriza-
tion, i.e., (1) whether and what extent main histological types,
whose classification still primarily relies on morphology, may be
credited by IHC; (2) whether such definitions of tumor pheno-
type are really based on the evidence of the current classification
on lung cancer; and (3) whether biopsies are actually adequate
material to undergo this task. In fact, whether it is legitimate to
take operative decisions on patients on the basis of diagnostic
adjuncts other than morphology, it is still matter of debate. Most
published studies have compared IHC on biopsy or cytology
with morphology on surgical specimens or have extended diag-
nostic algorithms primarily devised on surgical specimens to
biopsy or cytology samples.16–20,27–31 Little, however, is known
about the accuracy of preoperative and unselected small biopsies
to faithfully parallel IHC profiles and, hence, eventual diagnoses
on surgical specimens.
This study was aimed at comparatively evaluating the
predictive role of IHC on preoperative and unselected biopsies
to subtype NSCLC by means of a widely agreed-on and tradi-
tional antibody panel approach, relying on the corresponding
surgical specimens as the gold standard for morphology and
IHC. We hypothesized that IHC-assessed small biopsies by
using TTF1, cytokeratins 5/6 and 7, p63, and vimentin could
effectively parallel the corresponding profiling and, hence, even-
tual diagnoses on surgical specimens. As a matter of fact, the
large majority of tumors were consistently forecasted on biopsy,
relative also to the recognition of demanding histologies, such as
sarcomatoid or adenosquamous carcinoma.
PATIENTS AND METHODS
Patients and Tumors
A series of 63 consecutive preoperative biopsies of
NSCLC and corresponding surgical specimens from 54 men
(range, 39–85 years) and nine women (range, 40–76 years)
were identified in the archives of the Divisions of Pathology of
the European Institute of Oncology of Milan and the Azienda
Ospedaliera-Universitaria Policlinico of Modena. The time
frame was 2005–2008 for all tumors with the exception of
sarcomatoid (plemorphic type) carcinomas, which spanned a
longer time frame (2004–2009) because of their inherent rarity.26
Criteria for entering the investigation (approved by the insti-
tutional review board) also included the lack of a history of
cancer elsewhere in the body or neoadjuvant therapy before
performing biopsies. The study comprised 31 fiberoptic bron-
choscopy biopsies, 26 transcutaneous core biopsies of pulmo-
nary nodules, three transbronchial biopsies, and three transcuta-
neous core biopsies of peripheral lymph nodes, with the
corresponding surgical specimens consisting of lobectomy,
pneumonectomy, or lymph node excision. The patients com-
prised 37 current, 23 former, and three nonsmokers (the latter
including two adenocarcinomas and one squamous cell carci-
noma). All biopsies and surgical specimens had been fixed in
4% buffered formaldehyde solution for 12 to 24 hours and
embedded in paraffin according to standard histopathologic
methods. No special stains were used to highlight mucous
deposition in tumor cells because of too low sensitivity rate as
recently reported on.17,18 All the original hematoxylin and eosin
(H&E)-stained sections were blindly reviewed by two experi-
enced pathologists in lung cancer (G.P. and G.R.) without
knowledge of patients’ identity or original tumor categorization
on either biopsy or surgical specimens according to the 2004
World Health Organization classification criteria on lung tu-
mors,1 assuming that revised surgical specimens made up the
gold standard for any comparison. All tumors were categorized
as much definitively as possible, avoiding diagnosing NSCLC,
not otherwise specified or large cell carcinoma.1 In particular,
sarcomatoid carcinoma was defined by the concurrence of any
NSCLC and sarcomatoid (giant and/or spindle cell) components
or by giant and spindle tumor cells alone,32,33 whereas large cell
neuroendocrine carcinoma was excluded by morphology and
IHC of panendocrine markers.1 In the event of diagnostic dis-
crepancy, consensus was reached by the combined reevaluation
of relevant slides at a two-headed light microscope (interob-
server agreement was not assessed in this study). So settled, the
study comprised 30 squamous cell carcinomas (seven G2 and 23
G3 tumors), 22 adenocarcinomas (one G1, eight G2, and 13 G3
tumors), eight sarcomatoid carcinomas (all G3 tumors by defi-
nition, composed of adenocarcinoma in five cases or squamous
cells carcinoma in three cases and of sarcomatoid component),
two adenosquamous carcinomas (all G3 tumors), and one pri-
mary yolk sac tumor.
Immunohistochemical Evaluation
Four-micron-thick sections were reacted for 30 minutes
with the antibody panel listed in Table 1 and then incubated
with a commercially available detection kit (DAKO EnVision
Plus-HRP, Dako, Glostrup, Denmark) following the manu-
facturer’s instructions and previously refined IHC methods.23
IHC for CK5/6, CK7, p63, and TTF1 was carried out on all
the 63 cases, whereas vimentin was tested on 53 only. The
specificity of all reactions was checked replacing the primary
antibody with a nonrelated mouse immunoglobulin at a com-
parable dilution or using normal serum alone. Positive and
negative controls were used as appropriate. Immunoreactivity
was rendered semiquantitatively on a scale from negative to
5, taken into account the entire tumor area on paraffin-
blocked samples and the subcellular localization of antibodies
(cytoplasms for vimentin and cytokeratins; nuclei for TTF1
and p63). Tumors were considered negative if staining was
completely absent in the relevant cells; 1 cases showed
immunoreactivity in up to 10% neoplastic cells, 2 cases in
11 to 25% neoplastic cells, 3 cases in 26 to 50% neoplastic
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cells, 4 cases in 51 to 75% neoplastic cells, and 5 cases in
76 to 100% neoplastic cells. This choice was determined by
the need of minimizing variability in slide assessment when
trying punctual percentages. In event of discrepancy, consen-
sus was reached by the same combined reevaluation with
two-headed light microscope as the morphologic assessment.
Statistical Analysis
Qualitative data were compared by analysis of variance
and Fisher’s exact test and correlations carried out by Spear-
man’s rank test or Pearson product-moment correlation co-
efficient. Unsupervised and supervised hierarchic clustering
analysis was performed according to previously reported
methods.34,35 The diagnostic performance of IHC was eval-
uated by approaching receiver operating characteristic (ROC)
analysis. Briefly, each value of the relevant markers was used
as a cut point to calculate sensitivity and specificity, thereby
defining the curve and the area under the curve (AUC) with
corresponding 95% confidence intervals. ROC curves were then
compared by Z test, for which the distribution of the test statistic
under the null hypothesis can be approximated by a normal
distribution.36 All analyses were carried out using the SAS
statistical software (SAS Institute, Inc., Cary, NC), taking into
account two-sided testing and p less than 0.05 as significant.
RESULTS
Diagnosing H&E-Stained Tumors
Comparison between original and revised diagnoses on
biopsy samples according to surgical specimens is presented in
Table 2. There were 42 of 63 (67%) versus 53 of 63 (84%)
correctly classified tumors on biopsy before and after revision,
respectively. Major sources of inconsistency were two cases of
adenosquamous carcinoma (for the lack of composite histology),
seven cases of sarcomatoid carcinomas (for the lack of diagnos-
tic spindle and/or giant cell component), and one case of yolk
sac tumor (for the lack of characteristic histological features).
Sensitivity, specificity, positive predictive value, negative pre-
dictive value, and diagnostic accuracy rates of revised biopsies
were 100%, 88%, 88%, 100%, and 94% for squamous cell
carcinoma; 100%, 85%, 79%, 100%, and 90% for adenocarci-
noma; and 13%, 100%, 100%, 89%, and 94% for sarcomatoid
carcinoma, respectively (Table 3, Revised biopsies versus sur-
gical specimens). No differences were found in the distribution
of age and gender among patients and tumor grades, thereby
minimizing biases due to patients’ selection.
Diagnosing Immunostained Tumors
Unsupervised hierarchical analysis identified five dis-
tinct tumor clusters in both surgical specimens (1A-surgical
specimen [SS], 1B-SS, 1C-SS, 2A-SS, and 2B-SS) and small
biopsies (1A-biopsy specimen [BS], 1B-BS, 1C-BS, 2A-BS,
and 2B-BS), which revealed the existence of a nonrandom
distribution of the relevant markers across the tumor series
under evaluation (Figures 1A, C, respectively). When tumors
were clustered for conventional histology according to super-
vised analysis, definite profiles were recognized for the main
tumor types in either type of material, with CK7- and TTF1-
positive tumors clustering with adenocarcinoma, CK5/6- and
TABLE 1. Antibody Panel Used in This Study
Antibodies Clone Source Dilution Pretreatment
Cytokeratin 7 OV-TL 12/30 DAKO, Glostrup, Denmark 1:400 Pepsina
TTF-1 8G7G3/1 NeoMarkers, Fremont, CA 1:1000 MWO-EDTA
p63 4A4 DAKO, Glostrup, Denmark 1:100 MWO-EDTA
Cytokeratin 5/6 D5/16 B4 DAKO, Glostrup, Denmark 1:50 MWO-EDTA
Vimentin V9 DAKO, Glostrup, Denmark 1:50 MWO-CB
a Digestion with 5% pepsin solution for 5 min.
MWO-EDTA, microwave oven at 750 W for 30 min in EDTA buffer pH8; MWO-CB, microwave oven at 750 W for 30 min in citrate
buffer pH6; EDTA, ethylenediaminetetraacetic acid; TTF1, thyroid transcription factor-1.
TABLE 2. Original and Revised Diagnoses by Morphology on Biopsy in Comparison with Surgical Specimens
Diagnoses
on Surgical
Specimens
No. of
Cases
Original Diagnoses on Biopsies Revised Diagnoses on Biopsies
Squamous
Cell
Carcinoma Adenocarcinoma
Sarcomatoid
Carcinoma
NSCLC
NOS pa
Squamous
Cell
Carcinoma Adenocarcinoma
Sarcomatoid
Carcinoma pa
Squamous cell
carcinoma
30 21 0 0 9 1.09E-09 30 0 0 1.04E-16
Adenocarcinoma 22 1 15 0 6 0 22 0
Sarcomatoid
carcinoma
8 1 1 1 5 2 5 1
Other 3 1b 1c 0 1b 2b 1c 0
a p value according to Fisher’s exact “t” test.
b Missing diagnoses of adenosquamous carcinoma.
c Missing diagnosis of yolk sac tumor.
NSCLC NOS, non-small cell lung cancer, not otherwise specified.
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FIGURE 1. Hierarchic unsupervised (A, C) and supervised (B, D) clustering analysis on both surgical specimens (SS in dia-
grams A and B) and biopsies (BS in diagrams C and D) across the entire tumor series under evaluation. A nonrandom distribu-
tion of the relevant markers was shown in both SS (A) and BS (C). Tumor clustering for conventional histology defined consis-
tent profiles to occur for the main tumor types in both SS (B) and BS (D). In particular, CK7 and thyroid transcription factor-1
[TTF1] highlighted adenocarcinoma (AC), CK5/6 and p63 squamous cell carcinoma (SCC), and vimentin sarcomatoid carci-
noma (SC) (other included two cases of adenosquamous carcinoma and a case of yolk sac tumor).
TABLE 3. Comparison of Revised Biopsies with Surgical Specimens by Morphology and Immunohistochemistry
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Diagnostic Accuracy
(95% CI)
Revised biopsies vs. surgical specimens
Squamous cell carcinoma 30/30 29/33 30/34 29/29 59/63
100 (80–100) 88 (72–97) 88 (73–97) 100 (88–100) 94 (85–98)
Adenocarcinoma 22/22 35/41 22/28 35/35 57/63
100 (85–100) 85 (71–94) 79 (59–92) 100 (90–100) 90 (80–96)
Sarcomatoid carcinoma 1/8 55/55 1/1 55/62 56/63
13 (3–53) 100 (94–100) 100 (2–100) 89 (78–95) 94 (85–98)
Immunostained biopsies vs. surgical specimens
Squamous cell carcinoma 30/30 30/31 30/31 30/30 62/63
100 (88–100) 97 (83–100) 97 (83–100) 100 (88–100) 98 (91–100)
Adenocarcinoma 22/22 40/41 22/25 40/40 62/63
100 (85–100) 98 (87–100) 88 (69–97) 100 (92–100) 98 (91–100)
Sarcomatoid carcinoma 5/8 55/55 5/5a 55/58 60/63
63 (24–91) 100 (94–100) 100 (48–100) 95 (86–99) 95 (87–99)
Adenosquamous carcinoma 2/2 61/61 2/2 61/61 63/63
100 (16–100) 100 (94–100) 100 (16–100) 100 (94–100) 100 (94–100)
a One case initially diagnosed by morphology alone was, however, incorporated subsequently after vimentin labeling.
PPV, positive predictive value; NPV, negative predictive value; CI, confidence intervals.
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p63-positive tumors with squamous cell carcinoma, and vi-
mentin-positive tumors with sarcomatoid carcinoma (Figures
1B, D). Relative to surgical specimens and according to
semiquantitative IHC scores, adenocarcinoma was character-
ized by CK7 expression in at least 25% tumor cells and TTF1
in at least a few tumor cells (rarely expressing CK5/6 and
p63, the latter ranging from focal to 50%); squamous cell
carcinoma was defined by p63 and CK5/6 labeling in at least
25% tumor cells (never expressing TTF1 and, only focally or
less than 50%, showing CK7 labeling); and sarcomatoid
carcinoma was highlighted by vimentin immunoreactivity in
50 to 100% tumor cells with variable expression of glandular
(CK7 and TTF1) and/or squamous (p63 and CK5/6)
differentiation. CK7 immunoreactivity in squamous cell car-
cinoma was fainter and erratic than in adenocarcinomas or the
glandular component of adenosquamous carcinomas, where
there was a stronger and diffuse cytoplasmic labeling of
tumor cells. Adenosquamous carcinoma exhibited a compos-
ite phenotype, with CK7, CK5/6, or p63 immunoreactivity in
up to over 50% but not TTF1. The primary yolk sac tumor
case was negative for all the relevant markers (Figure 1B and
Table 4).
Pairwise comparison for each marker between any two
samples, as shown in the two-dimensional diagrams of unsu-
pervised (Figure 2A) and supervised (Figure 2B) hierarchical
clustering, resulted in close correlation coefficients ranging
from 0.61 for vimentin to 0.96 for TTF1 (Figure 2C). Mosaic
plot analysis confirmed a close and distinct relationship of the
clusters with the diverse tumor categories in both surgical
specimens (Figure 3A) and biopsies (Figure 3B), as also
indicated by the impressive 0.977 Pearson correlation coef-
ficient between the two tissue series. ROC analysis showed
AUC values of 0.9399 and 0.9990 for p63; 0.9813 and 0.9995
for CK5/6; 0.9401 and 0.9216 for CK7; 0.8947 and 0.8884
for TTF1; and 0.9833 and 0.9875 for vimentin in surgical
specimens (Figure 4A) and small biopsies (Figure 4B), re-
spectively. No differences were found in the comparison of
AUC-ROC curves for each paired marker between the two
TABLE 4. Distribution of the Five Immunohistochemical Markers
Marker
IHC
Score
Tumor Types as Defined on Surgical Specimensa
p
Squamous Cell
Carcinoma (n  30)
Adenocarcinoma
(n  22)
Sarcomatoid
Carcinoma (n  8)
Adenosquamous
Carcinoma (n  2)
CK7 Negative 21 0 3 0 0.0001
Up to 10% 2 0 0 0
11–25% 4 0 0 1
26–50% 3 3 2 0
51–75% 0 3 1 0
76–100% 0 16 2 1
TTF-1 Negative 30 4 4 2 0.0001
Up to 10% 0 1 1 0
11–25% 0 0 2 0
26–50% 0 3 1 0
51–75% 0 6 0 0
76–100% 0 8 0 0
CK5/6 Negative 0 21 4 0 0.0001
Up to 10% 0 1 1 0
11–25% 0 0 2 0
26–50% 3 0 1 1
51–75% 9 0 0 1
76–100% 18 0 0 0
p63 Negative 0 15 4 0 0.0001
Up to 10% 0 3 1 0
11–25% 0 1 2 0
26–50% 4 1 0 0
51–75% 1 2 0 2
76–100% 25 0 1 0
Vimentinb Negative 17 12 0 1 0.0001
Up to 10% 3 1 0 1
11–25% 1 1 0 0
26–50% 0 5 0 0
51–75% 3 0 1 0
76–100% 0 1 6 0
a The case of yolk sac tumor, negative for all markers under evaluation, is not presented in the table.
b Only 53 tumor surgical samples were tested for vimentin (one case of sarcomatoid carcinoma was not stained).
IHC, immunohistochemistry.
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FIGURE 2. Two-dimensional diagrams reporting the pairwise comparison for each marker between any two samples accord-
ing to unsupervised (A) and supervised (B) hierarchical clustering analyses. High coefficients of correlation (C) were found for
each marker between surgical specimens (marked as SS) and biopsies (marked as BS) (AC: adenocarcinoma; SCC: squamous
cell carcinoma; SC: sarcomatoid carcinoma; other: two adenosquamous carcinomas and one yolk sac tumor).
FIGURE 3. Mosaic plot diagrams (the more surface of varying colored rectangles, the more amount of cases in the different
tumor subsets) confirmed a close and distinct relationship of the clusters with the diverse tumor categories in surgical speci-
mens (A) and biopsies (B). AC, adenocarcinoma; SCC, squamous cell carcinoma; SC, sarcomatoid carcinoma (the two cases of
adenosquamous carcinoma and the case of yolk sac tumor were excluded from this analysis).
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types of samples, with the exception of p63 that paralleled
more effectively the diagnosis of squamous cell carcinoma on
biopsy than surgical specimen (Table 5).
Comparison between IHC diagnoses on surgical spec-
imens and revised biopsies is shown in Table 6, Diagnoses on
surgical specimens, in keeping with the above-detailed diag-
nostic algorithms. Practically, 59 of 63 (94%) of tumors were
correctly classified by IHC, including 30 squamous cell
carcinomas, 22 adenocarcinomas, two adenosquamous carci-
nomas, and four sarcomatoid carcinomas. The sensitivity,
FIGURE 4. Area under the curve (AUC)-receiver operating characteristic (ROC) analysis curves for the different markers are
shown in both surgical specimens (A) and small biopsies (B). The high values of the AUC in both types of material testified the
high performance of IHC to correctly classify squamous cell carcinoma (p63 and CK5/6), adenocarcinoma (CK7 and thy-
roid transcription factor-1 [TTF1]), and sarcomatoid carcinoma (vimentin). The two cases of adenosquamous carcinoma
and the case of yolk sac tumor were excluded from the analysis for the sake of simplicity.
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specificity, positive predictive value, negative predictive
value, and diagnostic accuracy rates of IHC on biopsy
were then 100%, 97%, 97%, 100%, and 98% for squamous
cell carcinoma; 100%, 98%, 88%, 100%, and 98% for
adenocarcinoma; 63%, 100%, 100%, 95%, and 95% for
sarcomatoid carcinoma; and 100% for all parameters
for adenosquamous carcinoma, respectively (Table 3, Im-
munostained biopsies versus surgical specimens).
Challenging diagnoses in biopsy were sarcomatoid car-
cinoma and adenosquamous carcinoma. Sarcomatoid carci-
noma was correctly identified by vimentin IHC in 50 to 100%
tumor cells of four of seven (57%) cases (one case was
initially not assessable for this marker) with strong and
diffuse decoration of the cytoplasm as opposed to fainter,
incomplete, or basolateral cytoplasmic labeling of six adeno-
carcinomas and three squamous cell carcinomas, which was
independent of the semiquantitative assessment. Three other
sarcomatoid carcinomas containing only epithelial-appearing
cells in biopsy showed 0 to 1 vimentin immunoreactivity,
so the final diagnosis was adenocarcinoma (two cases) or
squamous cell carcinoma (one case). Adenosquamous differ-
entiation was suggested in two biopsies by sharing CK5/6 and
p63 in 25 to 50% tumor cells and CK7 in up to over 75%
tumor cells, the latter as strong and diffuse decoration of the
cytoplasm.
DISCUSSION
The main purpose of our article was not to reinvent
lung cancer classification through IHC by providing alterna-
tive classification schemes but rather to objectify subjectivi-
ties and limits underlying morphologic evaluation by testing
the hypothesis that IHC-assessed small biopsies effectively
paralleled the corresponding profiling and eventual diagnoses
on surgical specimens. Suffice it to say that historical and
practical reasons have thus far made morphology privilege
over other diagnostic adjuncts,37 mainly due to the lack of a
clinical reason to classify tumors more precisely.
An issue we addressed in our article was whether and
what extent main histological types, whose classification still
primarily relies on morphology in most cases, may be cred-
ited by IHC. No doubts that IHC has enormously sharpened
our diagnostic, prognostic, and predictive capabilities in lung
cancer influencing the prevalence of how lung tumors are
ultimately classified especially when referring to poorly dif-
ferentiated lesions.13,14,37–39 Nevertheless, clinical trials dem-
onstrating clinical significance to NSCLC subtyping have
thus far been primarily based on morphology11 leaving un-
settled the issue whether IHC on small biopsies may credit
final diagnoses of lung cancer, even though the relative
contribution of IHC assessment in these studies is difficult to
ascertain, but this information will have to be included in
future clinical trials. Immunophenotypes of the main histo-
logical types of lung cancer are deemed to be stable and
highly reproducible in most cases, with TTF1 and CK7
paralleling the glandular differentiation of adenocarcinoma
and CK5/6 and p63 the keratinizing differentiation of squa-
mous cell carcinoma.13,14,21,37 A combination of these mark-
ers is observed in composite tumors such as adenosquamous
carcinoma,1 whereas the epithelial-mesenchymal transition,
which is a prerogative of sarcomatoid lung carcinoma, is
faithfully highlighted by vimentin.25,26,37
In our study, the hierarchic clustering analysis showed
a nonrandom distribution of the relevant markers to occur
across the entire series of tumors, not only when dealing with
the surgical specimens but also even on small biopsies in
keeping with the assumption that IHC was effective to un-
ravel diverse cell lineages among NSCLC. Furthermore,
definite algorithms were noted to cluster according to the
current classification scheme of lung cancers1 on our series of
both surgical samples (Figure 1B) and biopsies (Figure 1D).
So, the couples CK7 and TTF1, or CK5/6 and p63 paralleled
adenocarcinoma and squamous cell carcinoma, respectively,
whereas a mixture of them highlighted adenosquamous car-
cinoma and a strong and diffuse vimentin in most tumor cells
pointed to sarcomatoid carcinoma. Although a few squamous
cell carcinomas presented CK7 decoration of the cytoplasm
in a minority of tumor cells, the relevant immunoreactivity
was fainter and more erratic than in adenocarcinomas or the
glandular component of adenosquamous carcinomas, where
there was a strong diffuse cytoplasmic labeling of tumor
cells. Further studies, however, are warranted to solidify
these preliminary findings. Anyhow, the superimposition of
profiles according to histology between the two types of
material confirmed the premise that the diverse categories
of IHC-driven tumors closely predicted conventional mor-
phology, i.e., the main tumor types, with immunoprofiles that
were stable and reproducible.
In particular, 25 to 50% positive tumor cells were
needed for a given marker to fulfill diagnostic algorithms of
a given tumor category on either type of sample. The only
remarkable exception held true for TTF1, which pointed
straightforwardly to the diagnosis of adenocarcinoma (once
excluded large cell neuroendocrine carcinoma)1 even when
focal and faint, independently of the concurrence of other
markers. Another interesting observation regarded p63,
TABLE 5. Comparison between AUC-ROC Curves for each
Paired Marker between the Two Types of Samples
AUC SE
95%
Lower
CI
95%
Upper
CI pa
p63-SS 0.9399 0.0279 0.8800 0.9900
p63-BS 0.9990 0.0012 0.9900 1.0000 0.0343
CK5/6-SS 0.9813 0.0119 0.9500 1.0000
CK5/6-BS 0.9995 0.0007 0.9900 1.0000 0.1268
CK7-SS 0.9401 0.0279 0.8800 0.9900
CK7-BS 0.9216 0.0358 0.8500 0.9900 0.6836
TTF1-SS 0.8947 0.0463 0.8000 0.9800
TTF1-BS 0.8884 0.0432 0.8000 0.9700 0.9208
Vimentin-SS 0.9833 0.0137 0.9500 1.0000
Vimentin-BS 0.9875 0.0127 0.9600 1.0000 0.8221
a p value according to Z test (see Statistical Analysis section).
SS, surgical specimen; BS, biopsy sample; AUC, area under curve; SE, standard
error; TTF1, thyroid transcription factor-1; CI, confidence interval.
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whose absence or occurrence in less than 25% tumor cells
allowed any diagnosis of squamous cell carcinoma to be
reasonably excluded. Negativity for TTF1, CK7, p63, and
CK5/6 was seen in a case of sarcomatoid carcinoma, which
was strongly and diffusely positivity for vimentin. Lack of
TTF1 and absence or minimal occurrence of p63 and CK5/6
were consistent with adenocarcinoma, in turn exhibiting
strong and diffuse decoration of tumor cells for CK7. The
combination of TTF1, CK7, CK5/6, and p63, we have re-
cently claimed as reliable for subtyping NSCLC,9 has also
been confirmed as the best, minimal IHC algorithm in a
model dealing with tissue microarrays.20 The lack of staining
for any marker of our “NSCLC-oriented” panel, as seen in the
case of yolk sac tumor, although made the diagnosis of
squamous cell carcinoma (lack of p63 and CK5/6), TTF1-
negative adenocarcinoma (lack of CK7), and sarcomatoid
carcinoma (lack of vimentin) quite unlikely, should alert
about the possibility of facing with an uncommon pulmonary
tumor type or an unsuspected metastasis (Figure 5).
The strategy of semiquantitative assessment allowed us
not only to minimize the well-known drawback of overlap-
ping phenotypes when undergoing multiparametric IHC21
with no adequate scoring thresholds for positivity but also to
highlight the dual cell differentiation of poorly differentiated
adenosquamous carcinomas where morphology on biopsy
was not conclusive. The high predictive values of this IHC-
driven classification (Table 3) confirmed the value of tumor
immunoprofiling on biopsy if a scoring system was taken into
account for classification, as well as the evidence-based
observation that these IHC-defined tumors largely merged
into the current classification scheme of lung cancer. The lack
of differences in AUC-ROC curves for CK7, TTF1, CK5/6,
and vimentin between the two types of samples, the high
correlation coefficients after pairwise comparison for each
marker between any two samples, the striking overlap of the
mosaic plots between clusters, and diverse tumor categories
in both surgical specimens and biopsies were further proofs
supporting the belief that biopsies were as reliable as surgical
FIGURE 5. Simple rules one should follow for
the correct subclassification of NSCLC in bi-
opsy samples when using a five-hit, NSCLC-
oriented antibody panel approach with thyroid
transcription factor-1 (TTF1), CK7, CK5/6, p63,
and vimentin.
TABLE 6. Correlation between Immunohistochemical Diagnoses on Biopsies and Morphology
Diagnosis on Biopsies by Immunohistochemistry
No. of
Cases
Squamous Cell
Carcinoma Adenocarcinoma
Sarcomatoid
Carcinoma
Adenosquamous
Carcinoma pa
Diagnoses on surgical specimens
Squamous cell carcinoma 30 30 0 0 0 0.001
Adenocarcinoma 22 0 22 0 0
Sarcomatoid carcinoma 8b 1 2 4 0
Adenosquamous carcinoma 2 0 0 0 2
Other 1 0 1c 0 0
Revised diagnoses on biopsies
Squamous cell carcinoma 34 31d 0 1 2 0.001
Adenocarcinoma 28 0 25e 3 0
Sarcomatoid carcinoma 1b 0 0 0 0
a p value according to Fisher’s exact “t” test.
b One case was evaluated by morphology only.
c Missing diagnosis of yolk sac tumor.
d Missing diagnosis of one sarcomatoid carcinoma.
e Missing diagnoses of two pleomorphic carcinomas and the yolk sac tumor.
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specimens for IHC to diagnose different tumor categories.
Interestingly, p63 paralleled the diagnosis of squamous cell
carcinoma more effectively on biopsy than surgical specimen
(Table 5 and Figure 4), probably due to casual factors, albeit
the AUC of ROC analysis was by far greater than 90% in
either type of material under evaluation.
The percentage of correct diagnoses on biopsy arose
from 67% by original site pathologists and 84% by expert
pathologists (both with morphology only) to 94% with this
IHC-driven classification approach. The 88% positive predic-
tive value for adenocarcinoma diagnosis after IHC was af-
fected by the case of yolk sac tumor, which was negative for
all markers,40 and three cases of sarcomatoid carcinoma,
which featured epithelial component only. Interestingly, al-
though there were no misclassifications between adenocarci-
noma and squamous cell carcinoma diagnoses by IHC in
comparison with revised morphology, the major contributors
to below-perfect accuracy was given by sarcomatoid and
adenosquamous carcinoma diagnoses, which could also be
highlighted. Albeit unusual tumors, such as yolk sac tumor or
unsuspected metastasis, would have not been properly clas-
sified by means of our “NSCLC-oriented” panel approach,
these possibilities should prompt to extend the criterion of
multidisciplinary setting to all situations where tumor pheno-
type is ambiguous or unclassifiable.
The diagnosis of sarcomatoid carcinoma using small bi-
opsy specimens has recently been argued against,41,42 even
though it may be suggested or at least suspected on biopsy16,43
and even cytology or cell blocks1,32,33,44 even by morphology.
To this regard, we introduce the use of vimentin IHC to make
a diagnosis of sarcomatoid carcinoma on small biopsies more
reliable, just as previously demonstrated on surgical speci-
mens too.25,26,45 Splitting the diverse types of sarcomatoid
carcinomas may be indeed unwarranted in light of the obser-
vation that these tumors share similar clinical presentation
and behavior.26 As EGFR and KRAS gene mutations have
been quite variably reported in sarcomatoid carcino-
mas42,45–47 and novel therapy options could stem also from
targeting epithelial-mesenchymal transition,26 it is clinically
relevant to highlight these changes in small biopsies by
exploiting vimentin IHC. Of course, these results are prelim-
inary, and further studies are in progress in our laboratory to
conform, on a larger number of cases, the capability of
vimentin to reproducibly detect sarcomatoid carcinomas.
The dogma that lung cancer subclassification has to rely
exclusively on standard H&E-stained sections rather than
under the guidance of findings stemming from IHC1 has
recently been questioned, particularly when dealing with
small biopsies and cytology,10 and has been addressed in the
new, just published, multidisciplinary classification of lung
adenocarcinoma authored by the International Association for
the Study of Lung Cancer, American Thoracic Society and
European Respiratory Society.48 Our study could contribute
to this debate, increasing the level of evidence that an IHC-
assessed small biopsy strategy mirrors the corresponding
profiling and, hence, eventual diagnoses on surgical speci-
mens. In our tumor series, there were no cases of large cell
carcinoma (that unquestionably should not be diagnosed on
small biopsy or cytology),1 because they disappear after profil-
ing by IHC, extensive blocking, or sectioning.15,28,39 Neverthe-
less, the meaning of this heterogeneity with respect to multimo-
dality therapy is still debated, although in the recent study by
Scagliotti et al.11 on the superiority of cisplatin/pemetrexed
regimen in nonsquamous NSCLC, large cell carcinoma histol-
ogy stratified along with adenocarcinoma.
In conclusion, our study demonstrates for the first time
that IHC on small biopsies reflected effectively the correct
ultimate profiling and diagnoses on surgical specimens per-
formed in keeping with the current lung cancer classification,
paving the way to novel diagnostic perspectives in clinical
trials on lung cancer and to the need of strategically preserv-
ing diagnostic material for molecular assays.
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